SOURCE: Peak Pharmaceuticals, Inc.

Peak Pharmaceuticals, Inc.

February 26, 2015 08:55 ET

Peak Pharmaceuticals Contracts With GMP Compliant Manufacturer

Company Scales Production of Canna-Pet™ Capsule Products to Meet Growing Demand

BOULDER, CO--(Marketwired - Feb 26, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) ("Peak Pharma" or the "Company"), a growth stage company aiming to become a leader in the research, development, sales and marketing of safe, hemp-based, medicinal products and supplements for both humans and animals, today announced entry into a contract manufacturing relationship aimed at increasing capacity to meet growing demand for the Company's Canna-Pet™ product lineup.

The manufacturer, who can't be named at this time for commercial reasons, operates an FDA compliant "current good manufacturing practices" (cGMP) certified state-of-the art manufacturing facility and specializes in health and beauty products. The company has a track record in nutraceutical and supplement manufacturing, enabling its customers to scale production with minimal risk and without investment in capital intensive infrastructure.

Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang notes, "We are very pleased to join forces with this professional and experienced manufacturing team. We view this move as an important step forward for Peak Pharma at multiple levels. The use of an established manufacturer offers the infrastructure to scale beyond our current capacity, enabling us to meet the growing demand for our popular Canna-Pet™ animal health products, as well as the cGMP required for us to provide true pharma grade products. Furthermore, we plan to leverage this relationship to make our first pilot scale, cGMP-level, human products for testing and launch in the very near future. As we continue to execute our business plan and market expansion strategy, we remain committed to our mission to launch innovative products for the human health market, and to fulfil our vision to become the number one veterinarian recommended hemp product on the market today."

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.

About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products. For more information visit www.peakpharma.com and follow us on Facebook, Twitter and LinkedIn.

About Canna-Pet™ Products for Pet Health
Canna-Pet™ is one of the first cannabinoid (CBD) product designed specifically for cats and dogs. Available over-the-counter, Canna-Pet™ produces veterinarian recommended, legal, cannabidiol (CBD) products for animals, made from industrial hemp and manufactured in the USA. Canna-Pet® products contain not only CBD, but carefully controlled ratios of other cannabinoids and terpenes which make the products uniquely effective. Now available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). For more information visit: www.canna-pet.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.

Contact Information